ClinicalTrials.gg
RecruitingNCT07463846Updated Nov 12, 2026

A Study to Evaluate ALN-2232 in Participants With Obesity

A Phase 1/2 interventional study of ALN-2232 and Placebo in Obesity, sponsored by Alnylam Pharmaceuticals. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Alnylam Pharmaceuticals · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 13, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 574 studies in Obesity with a site in Canada — 101 open to participants now, 150 under way, 46 of them phase 3. Obesity · Canada.

Planned enrollment
159th of 479
156 · median 73
Started
2026
with 52 others
Phase 1/2
10 of 574
1 open now
Primary completion
2027-04
later than 67 of 149 live
Registered
541st of 574
by date

Among the 574 studies in Obesity with a site in Canada, this one is the 159th largest by planned enrollment of the 479 interventional ones that give a count, is one of 53 that started in 2026, is one of 10 in phase 1/2, reaches primary completion later than 67 of the 149 other live ones, and was the 541st registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

101 of the 574 studies in Obesity with a site in Canada are open now. Recruiting first, the newest first:

96 more — sign in →

All 101 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 574 studies in Obesity with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to:

  • evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity
  • evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity
  • evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity
03

Conditions studied

  • Obesity

Browse trials for

Keywords

  • siRNA, RNAi therepeutic
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Parts:

  • Has a (BMI) of ≥30 kg/m\^2 and \<40 kg/m\^2
  • Has a (HbA1c) \<6.5%

Exclusion criteria

Exclusion Criteria:

All Parts:

  • Has any concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results
  • Receiving therapies for chronic weight management or antidiabetic medications

Note: other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
156 participants (estimated)

Study arms

  • Experimental
    Part A: ALN-2232

    Participants will be administered a single dose of ALN-2232

    Drug: ALN-2232

  • Placebo comparator
    Part A: Placebo

    Participants will be administered a single dose of placebo

    Drug: Placebo

  • Experimental
    Part B: ALN-2232

    Participants will be administered multiple doses of ALN-2232

    Drug: ALN-2232

  • Placebo comparator
    Part B: Placebo

    Participants will be administered multiple doses of placebo

    Drug: Placebo

  • Experimental
    Part C: ALN-2232

    Participants will be administered multiple doses of ALN-2232

    Drug: ALN-2232 · Drug: Tirzepatide

  • Placebo comparator
    Part C: Placebo

    Participants will be administered multiple doses of placebo

    Drug: Placebo

  • Other
    Part C: Tirzepatide

    Participants will be administered multiple doses of tirzepatide once weekly

    Drug: Tirzepatide

Interventions

  • DrugALN-2232

    ALN-2232 will be administered subcutaneously (SC)

  • DrugPlacebo

    Placebo will be administered SC

  • Tirzepatide will be administered SC

06

What researchers measure

Primary outcomes

  1. Part A: Frequency of Adverse Events (AEs)

    Time frame: Up to 12 months

  2. Part B: Percent Change from Baseline in Body Weight

    Time frame: Baseline up to Month 6

  3. Part C: Percent Change from Baseline in Body Weight

    Time frame: Baseline up to Month 6

Secondary outcomes

  1. Part A: Change from Baseline in Proteins in Adipose Tissue

    Time frame: Baseline up to Month 12

  2. Part A: Area Under the Plasma Concentration-time Curve (AUC) of ALN-2232 in Plasma

    Time frame: Predose and up to 15 days postdose

  3. Part A: Maximum Observed Plasma Concentration (Cmax) of ALN-2232 in Plasma

    Time frame: Predose and up to 15 days postdose

  4. Part A: Time to Maximum Plasma Concentration (Tmax) of ALN-2232 in Plasma

    Time frame: Predose and up to 15 days postdose

  5. Part A: Fraction of ALN-2232 excreted in urine

    Time frame: Predose and up to 8 days postdose (fe)

  6. Part A: Percent Change from Baseline in Body Weight

    Time frame: Baseline up to Month 12

  7. Part B and Part C: Concentrations of ALN-2232 in Plasma

    Time frame: Predose and up to 6 months postdose

  8. Part B and Part C: Percent Change from Baseline in Body Weight

    Time frame: Baseline up to Month 12

  9. Part B and Part C: Change from Baseline in Body Fat Mass and Lean Mass

    Measured by dual x-ray absorptiometry (DXA)

    Time frame: Baseline up to Month 12

07

Study locations

1 of 1 sites recruiting
  • Clinical Trial Site
    Mount Royal, H3P 3P1, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the US and/or the EU. Access to data may be declined where there is likelihood a patient could be identified or other feasibility issue, where there is a potential conflict of interest, planned business activities or an actual or potential competitive risk. Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Timeframes for data access may vary and can take up to 6 months or more. Requests for access to data can be submitted via the website www.vivli.org. Questions can also be directed to datasharing@alnylam.com.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Apr 2027, 13 months after the start.

Of 62 phase 1/2 interventional studies under Obesity, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's planned 13 months is below that.

Completion moved once since we started tracking on Sep 25, 2026: Mar 2028 → Apr 2028, on Oct 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2026
First posted
Mar 11, 2026
StartActual
Mar 2, 2026
Primary completionEst.
Apr 28, 2027
CompletionEst.
Apr 28, 2028was Mar 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Apr 27, 2027→Apr 28, 2027
Oct 13, 2026
Study completion
Mar 2, 2028→Apr 28, 2028
Oct 13, 2026
Show all 2 updates
  1. Nov 12, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 13, 2026
    Primary completion Apr 27, 2027→Apr 28, 2027
    Study completion Mar 2, 2028→Apr 28, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07463846
Responsible party
Sponsor
First posted
Mar 11, 2026
Start date
Mar 2, 2026
Primary completion
Apr 28, 2027 (estimated)
Completion
Apr 28, 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Alnylam Clinical Trial Information Line
Contact
clinicaltrials@alnylam.com
1-877-ALNYLAM
Alnylam Clinical Trial Information Line
Contact
clinicaltrials@alnylam.com
1-877-256-9526
Medical Director
study director · Alnylam Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion